Latest Headlines

Latest Headlines

UPDATED: Sanofi makes case for Fluzone superior clinical benefit label

In August, Sanofi gave a first look at eagerly anticipated data from Phase III comparing its high-dose Fluzone vaccine with a standard jab. The data prompted Sanofi to talk up its chances of getting a label for superior efficacy data in people aged over 65, and this week it began making its case.

Meta-analysis links flu vaccine to lower risk of heart attack and stroke

The discovery of a correlation between the flu vaccine and decreased risk of heart attack was met with skepticism earlier this year, particularly in light of GlaxoSmithKline's financial support of the study. But now, several months later, a new, more definitive analysis has identified the same trend.

CDC reports across-the-board rises in flu vaccine uptake

While the government shutdown has cast doubt on the Centers for Disease Control and Prevention's (CDC) ability to manage the upcoming flu season, officials can take some solace from last year's efforts. Flu vaccine uptake levels in adults, kids and health workers all trended upward last year.

Government shutdown forces CDC to halt seasonal flu program

Congress' failure to find a budget compromise and subsequent government shutdown has left CDC without the staff to carry out many of its functions, including the seasonal influenza program.

H7N9 vaccine may prove too little, too late

The H7N9 vaccine may arrive too late and with too little manufacturing capacity to really help, a New Scientist feature warns.

Pandemic leads researchers to universal flu vaccine 'blueprint'

Human immune systems were ill-prepared for the swine flu virus that spread across the globe in 2009. The lack of pre-existing immunity left people vulnerable but, researchers wondered, was everyone equally unprotected? Answering this question has led to a 'blueprint' for a universal flu vaccine.

European prices reapply old pressures to vaccine makers

The vaccine sector appears to be in good health. After coming through a period in which low profit margins and liability concerns deterred investment, EvaluatePharma now tips the sector to grow from $25 billion to $39 billion between 2012 and 2018. Yet, in some areas, old complaints can still be heard.

U.K. gov makes U-turn on link between GSK vaccine and narcolepsy

Evidence linking GlaxoSmithKline's swine flu vaccine to narcolepsy has mounted up this year, with new findings from Finland, Sweden and the United Kingdom emerging. Now, having previously knocked back compensation claims, the data has prompted the U.K. government to accept the link.

Visterra advances universal flu antibody to cusp of Phase I

Massachusetts-based biotech Visterra is preparing to move its universal influenza therapy into the clinic.

NIH trialing Sanofi H7N9 vaccine with GSK, Novartis adjuvants

Delivering a vaccine against an emerging pandemic flu strain requires developers to make a lot of quick decisions about dosing, use of adjuvants and other factors. With H7N9, however, China's success in limiting the virus' spread has given other countries more time to prepare.